학술논문

Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection
Document Type
article
Source
PLOS ONE. 7(11)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Brain Disorders
Infectious Diseases
Biomedical Imaging
Neurosciences
HIV/AIDS
Clinical Research
2.1 Biological and endogenous factors
Aetiology
Infection
Acute Disease
Adult
Anti-HIV Agents
Brain
Female
HIV Infections
Humans
Magnetic Resonance Spectroscopy
Male
Middle Aged
Neurons
Quality Control
Treatment Outcome
Young Adult
RV254/SEARCH 010 protocol teams
General Science & Technology
Language
Abstract
ObjectiveSingle voxel proton magnetic resonance spectroscopy (MRS) can be used to monitor changes in brain inflammation and neuronal integrity associated with HIV infection and its treatments. We used MRS to measure brain changes during the first weeks following HIV infection and in response to antiretroviral therapy (ART).MethodsBrain metabolite levels of N-acetyl aspartate (NAA), choline (tCHO), creatine (CR), myoinositol (MI), and glutamate and glutamine (GLX) were measured in acute HIV subjects (n = 31) and compared to chronic HIV+individuals (n = 26) and HIV negative control subjects (n = 10) from Bangkok, Thailand. Metabolites were measured in frontal gray matter (FGM), frontal white matter (FWM), occipital gray matter (OGM), and basal ganglia (BG). Repeat measures were obtained in 17 acute subjects 1, 3 and 6 months following initiation of ART.ResultsAfter adjustment for age we identified elevated BG tCHO/CR in acute HIV cases at baseline (median 14 days after HIV infection) compared to control (p = 0.0014), as well as chronic subjects (p = 0.0023). A similar tCHO/CR elevation was noted in OGM; no other metabolite abnormalities were seen between acute and control subjects. Mixed longitudinal models revealed resolution of BG tCHO/CR elevation after ART (p = 0.022) with tCHO/CR similar to control subjects at 6 months.InterpretationWe detected cellular inflammation in the absence of measurable neuronal injury within the first month of HIV infection, and normalization of this inflammation following acutely administered ART. Our findings suggest that early ART may be neuroprotective in HIV infection by mitigating processes leading to CNS injury.